LAMZEDE
Drug
Chiesi USA, Inc.
Total Payments
$309,480
Transactions
139
Doctors
78
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $94,155 | 86 | 54 |
| 2023 | $215,326 | 53 | 32 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $199,255 | 21 | 64.4% |
| Honoraria | $80,431 | 30 | 26.0% |
| Unspecified | $22,075 | 1 | 7.1% |
| Travel and Lodging | $4,423 | 12 | 1.4% |
| Food and Beverage | $3,115 | 73 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $181.67 | 2 | 0.1% |
Payments by Type
General
$287,406
138 transactions
Research
$22,075
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Analysis of Velmanase Alfa (Lamzede)s Effects in the Body of Children with Alpha-Mannosidosis Under the Age 3 (LAMPO(0-3)) | Chiesi USA, Inc. | $22,075 | 0 |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $309,480
Product Information
- Type Drug
- Total Payments $309,480
- Total Doctors 78
- Transactions 139
About LAMZEDE
LAMZEDE is a drug associated with $309,480 in payments to 78 healthcare providers, recorded across 139 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2023 to 2024. In 2024, $94,155 was paid across 86 transactions to 54 doctors.
The most common payment nature for LAMZEDE is "Consulting Fee" ($199,255, 64.4% of total).
LAMZEDE is associated with 1 research study, including "Analysis of Velmanase Alfa (Lamzede)s Effects in the Body of Children with Alpha-Mannosidosis Under the Age 3 (LAMPO(0-3))" ($22,075).